IMPORTANCE Whether genetic factors can identify patients at risk for radiation-induced fibrosis remains unconfirmed.
F or women with breast cancer, whole-breast irradiation (WBI) after breast-conserving surgery optimizes breast preservation rates and breast cancer-specific survival, yet it can also result in problems with normal tissues, including fibrosis and adverse cosmetic outcomes. [1] [2] [3] [4] [5] Unfortunately, excellent cosmesis is not universally attained following WBI, reflecting variability among patients in the extent to which the normal tissues of the breast are damaged by radiation therapy. Identifying factors associated with the risk of radiotherapy toxicities of normal tissue could be used to tailor local treatment decisions, such as radiation dosing and target volumes, to an individual's genomic profile. 6 Several studies support the hypothesis that the radiosensitivity of the breast is under genetic control. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] One such genomic candidate is the C−509T (rs1800469) variant allele of TGFB1 (GenBank NC_000019.10). A pleiomorphic cytokine, TGF-β plays an important role in normal and pathophysiological fibrogenesis by stimulating fibroblast migration, proliferation, and collagen release. 17, 18 The C−509T polymorphism has been associated with elevated gene expression and plasma levels of TGF-β, 19 and the presence of this polymorphism has been associated with increased risk of radiation-induced fibrosis in some 11, 12, 15, 16, 20 but not all 21, 22 retrospective studies. A recent prospective validation study failed to find an association between radiotherapy toxicities and TGFB1 polymorphisms, including C−509T, adding uncertainty to the predictive value of these genetic markers. 23, 24 However, the existing literature is limited by the use of multiple fibrosis scales that are variably sensitive to clinically significant changes. The objective of the present study was to prospectively assess whether an association existed between the TGFB1 C−509T variant allele and radiotherapy-induced toxicity of normal tissue following WBI. We hypothesized that this variant allele increases the risk of breast fibrosis as assessed using the Late Effects Normal Tissue/ Subjective, Objective, Medical Management, Analytic (LENT/ SOMA) scale. 25 The LENT/SOMA fibrosis subscale is a physician-reported 4-point ordinal grading system that has demonstrated improved sensitivity to the severity of fibrosis compared with the Radiation Therapy Oncology Group (RTOG) late radiation morbidity scale in a validation study evaluating a population of breast cancer survivors. 26 We also sought to explore whether any association existed between the TGFB1 C−509T variant allele and other patient-and physicianreported outcomes relevant to WBI. We tested our hypothesis in a cohort of 175 women who had participated in a randomized clinical trial comparing 2 WBI dosing regimens.
Methods

Patient Cohort
Between February 2011 and February 2014, 287 women aged 40 years or older with pathologically confirmed ductal carcinoma in situ or early invasive breast cancer (pTis, pT1, pT2, pN0, or pN1) were enrolled and randomized after breast-conserving surgery (trial protocol in Supplement 1). Patients were allocated to treatment with either hypofractionated WBI (42.56 Gy [to convert to rad, multiply by 100] in 16 fractions followed by a boost) or conventionally fractionated WBI (50 Gy in 25 fractions followed by a boost). Details regarding inclusion criteria and treatment planning have been previously reported. 27 The present study was reviewed and approved by the institutional review board at MD Anderson Cancer Center (Houston, Texas). Written informed consent was obtained from all study participants.
Genotyping
A total of 227 patients consented to venipuncture. Genomic DNA from the buffy coat fraction of the blood sample was extracted using a Gentra Puregene Blood Kit (Qiagen). The DNA purity and concentration were determined by spectrophotometer measurement of absorbance at wavelengths of 260 and 280 nm. The genotype at the C−509T TGFB1 allele was determined using real-time polymerase chain reaction analyses. The reaction was conducted using an Applied Biosystems 7500 system (Life Technologies) per the manufacturer instructions, with TaqMan Genotyping Master Mix and primer probes. The presence of at least 1 T-containing allele at position −509 relative to the first major transcription start site of the TGFB1 gene was defined as the risk exposure.
Breast Cancer (FACT-B) module trial outcome index. 30 Each instrument was administered when patients returned for a follow-up visit 3 years after completing radiotherapy. Secondary physician-reported outcomes included (1) cosmetic outcome assessed by the treating physician using the RTOG/Harvard scale; (2) telangiectasia assessed using the LENT/SOMA scale; (3) toxicity-related adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4 (CTCAE v4.0); and (4) cosmetic outcome assessed by a panel of 3 physicians (including B.D.S. and S.F.S.) blinded to treatment assignment and C−509T genotype who reviewed 5-view photographs (right lateral, right anterior oblique, anteroposterior, left anterior oblique, left lateral) obtained in the standing position framed from the neck to the umbilicus. Templates with definitions of all outcomes were provided to the physicians to assess and document outcomes. The panel assessing cosmetic outcomes comprised 2 oncologists with expertise in breast cancer-focused radiation (B.D.S. and S.F.S.) and a surgeon with expertise in surgical procedures for breast cancer who were blinded to randomization arm and genotype. The RTOG/Harvard scale was used to assess cosmesis, and consensus among the 3 physicians was achieved for each patient. 31 
Statistical Analysis
For the primary outcome, the trial was designed to yield 83% power to detect a 15% absolute difference in risk of grade 2 or higher fibrosis using LENT/SOMA criteria 3 years after completing radiotherapy. At a 1-sided significance level of .05, assuming that 150 patients participated in this component of the study, the baseline risk of fibrosis among the participants with the wild-type gene is 5%, and the frequency of the variant allele in the population is 0.33. This prespecified difference was based on the effect size of C−509T reported in prior retrospective studies that also used the LENT/SOMA fibrosis scale. 15, 16 The difference in the proportions of fibrosis by genotype was evaluated using the 1-sided Fisher exact test. Univariate and multivariable logistic regression models were subsequently used to identify factors associated with the outcome. The final multivariable logistic regression model included covariates associated with the outcome at 2-sided P < .05 as well as the randomization arm regardless of its statistical significance. The Firth bias correction method was used in the logistic regression models because the proportion of at least grade 2 fibrosis was less than 10%. 32 The statistical interaction of the randomization arm with the C−509T genotype was also tested in the multivariable model. For secondary patient-reported outcomes, the associations of C−509T genotype with BCTOS cosmesis and with functional status were assessed using the 2-sided Wilcoxon rank sum test. Association of genotype with patient-reported cosmetic outcome dichotomized at 2.5 or greater was assessed using the 2-sided Fisher exact test. Genotype associations with the Body Image Score and with the FACT-B trial outcome index were assessed using the 2-sided t test because both outcomes were normally distributed.
For secondary physician-reported outcomes, physicianassessed and photographically assessed cosmetic outcomes were dichotomized as either good or excellent vs fair or poor.
The associations of C−509T genotype with photographically assessed cosmetic outcome and with grade 2 or higher telangiectasia were assessed using the 2-sided Fisher exact test.
All statistical analyses were conducted using SAS, version 9.3 (SAS Institute Inc).
Results
Patients
In total, 432 patients were screened for eligibility. Of these, 300 patients were registered for protocol treatment, and 287 patients were randomized and evaluable ( Figure 1) . Of the 149 patients allocated to conventionally fractionated WBI, all 149 patients (100%) received the allocated treatment, and 112 patients (75%) had 3-year follow-up data, of whom TGFB1 genotype was assessed in 93 patients (62%). Of the 138 patients allocated to hypofractionated WBI, 137 (99%) received the allocated treatment, and 101 (73%) had 3-year follow-up data, of whom TGFB1 genotype was assessed in 82 patients (59%). Of the 175 patients with 3-year follow-up data and TGFB1 genotype assessment, 85 (49%) had the homozygous C/C genotype (−509C), 75 (43%) had the heterozygous T/C genotype, 14 (8%) were homozygous (T/T) for the C−509T allele, and 1 (1%) had undetermined allele information (eTable 1 in Supplement 2). The variant allele (T) frequency among these 175 patients was 0.296, and the alleles were confirmed to be in Hardy-Weinberg equilibrium. There were no significant differences in any baseline patient characteristics or clinical variables between patients for whom the C−509T genotype was or was not known (eTable 2 in Supplement 2).
Of the 174 patients who had nonmissing C−509T genotype data, 89 (51%) had at least 1 T allele. The T allele was present in 45 of 93 patients (48%) allocated to conventionally fractionated WBI and 44 of 81 patients (54%) allocated to hypofractionated WBI (P = .43). The distribution of C−509T was not equal across race/ethnicity, with the T allele present in 62 of 130 non-Hispanic white (48%), 18 of 24 Hispanic white (75%), and 6 of 17 black (35%) patients (P = .01). With the exception of taxane-based chemotherapy (administered to 34 of 89 patients [38%] with the C−509T allele compared with 18 of 86 patients [21%] homozygous for −509C [P = .01]), all other baseline patient, tumor, and treatment characteristics, including body mass index, cup size, tumor stage, tumor markers, and overall administration of chemotherapy, were well matched between groups (eTable 3 in Supplement 2). Examination of baseline postsurgical, preradiotherapy patient-and physicianreported outcomes revealed no differences in any measured outcome by C−509T genotype (eTable 4 in Supplement 2).
Primary End Point of Fibrosis
Three-year LENT/SOMA fibrosis and telangiectasia data were available for 167 of the 174 patients (96%) with C−509T genotype information. The overall rate of grade 2 or higher fibrosis was significantly higher among patients with a C−509T allele (12 of 87 patients [13.8%]) than among patients without the T allele (3 of 80 patients [3.8%]) (absolute difference, 10.0%; 95% CI, 1.7%-18.4%; P = .02) (eTable 5 in Supplement 2). No difference was noted in the rate of grades 2 to 3 telangiectasia by genotype (1.1% vs 3.8%; P = .35). The 3-year physicianassessed cosmesis data were available from the treating physician for 169 of the 174 patients (97%) with C−509T genotype data and from the physician panel for 169 patients (97%). The prevalence of treating physician-assessed fair or poor cosmesis (32.2% vs 23.2%; P = .19) or panel physician-assessed fair or poor cosmesis (34.9% vs 30.1%; P = .51) did not differ significantly for those with or without the C−509T allele, respectively.
For univariate logistic regression of factors associated with the outcome, only C−509T genotype (odds ratio [OR], 3.67; 95% CI, 1.07-12.60; P = .04) and baseline postsurgical, preradiotherapy panel physician-assessed cosmesis (OR, 6.42; 95% CI, 2.30-17.91; P < .001) were significantly associated with fibrosis risk (eTable 6 in Supplement 2). The C−509T genotype was not associated with baseline panel physician-assessed cosmesis (median [interquartile range] score of 2.00 [1.00-2.00] for patients with −509C vs 2.00 [1.00-2.00] for patients with C−509T; Wilcoxon rank sum test P = .88) (eTable 4 in Supplement 2). The final multivariable model included the C−509T genotype, baseline panel physician-assessed cosmesis, and randomization arm. The association between C−509T allele and fibrosis remained statistically significant after multivariable adjustment (OR, 4.47; 95% CI, 1.25-15.99; P = .02) (Table) The association between 3-year CTCAE v4.0-assessed toxicities and C−509T genotype is shown in eTable 9 in Supplement 2. No patients developed higher than grade 2 toxicity. Patients with the C−509T allele had a higher prevalence of grade 2 breast atrophy than patients without the variant allele (16.9% vs 7.1%; P = .047) (eTable 9 in Supplement 2). There was no difference in the prevalence by genotype of any other CTCAE v4.0-assessed grade 2 toxicities.
Discussion
The results of the present study showed that patients with at least 1 copy of the C−509T allele in the TGFB1 gene had an increased risk of developing fibrosis after WBI. The association of C−509T with fibrosis occurred independent of the radiotherapy fractionation regimen or postsurgical, preradiotherapy cosmesis, the only other factor associated with breast fibrosis. Homozygosity at the −509C allele appeared to confer protection against fibrosis, with only 3.8% of patients with this genotype exhibiting grade 2 or higher fibrosis compared with patients with at least 1 copy of the T allele at this locus, whose prevalence of grade 2 or higher fibrosis was 13.8%. This finding mirrors prior reports that similarly describe low rates of fibrosis among patients homozygous for the −509C allele. 15 To our knowledge, the present study is the first prospective validation of a genomic factor associated with late radiation fibrosis, substantiating a role for somatic genomic toxicity stratification in a clinical oncology population. A key challenge in identifying genetic risk factors of radiotherapy toxicity is to precisely, robustly, and sensitively define the outcomes of interest. Late toxicity was defined differently among previous studies, likely contributing to the unresolved association between TGFB1 single-nucleotide polymorphisms and radiation fibrosis. Our study used the LENT/SOMA scale, which provides an objective and validated scale of radiation-induced fibrosis that was strongly associated with the C−509T allele in a prior retrospective study. 15 Clinically significant fibrosis was defined in our study as grade 2 on the LENT/SOMA scale (ie, "definite increased density and firmness"), which is readily differentiated from grade 1 (ie, "barely palpable" fibrosis). 25 Yet our results conflict with the report from the Radiogenomics: Assessment of Polymorphisms for Predicting the Effects of Radiotherapy (RAPPER) study, a prospective validation study that evaluated multiple single-nucleotide polymorphisms and outcomes in a large multicenter clinical cohort. 23 In contrast to the LENT/SOMA scale described in the present study, the RAPPER study used the CTCAE, version 3, toxicity scale for fibrosis, defining grade 1 fibrosis as "increased density on palpation," compared with the definition of grade 2 as "marked increase in density and function on palpation with or without minimal retraction." This instrument is insensitive to the separation observed between grades 1 and 2 on the LENT/SOMA scale, as evidenced by only a single patient being scored as having grade 2 fibrosis in the RAPPER study. 24 Thus, despite a large cohort size, the RAPPER study likely lacked the power to detect genetic contributions to fibrosis owing to an insensitive event definition and low event rate. The positive association reported in the present study reinforces the importance of outcome measure selection in identifying genetic risk factors for late toxicity. Fibrosis was chosen as a clinically meaningful end point for the present study because it provides a plausible biological mechanism for multiple other adverse outcomes, including decrements in cosmesis, function, and quality of life. We found that the C−509T allele was associated with increased risk of breast fibrosis and that this allele may increase risk of worse functional outcomes and breast atrophy, specific morbidities that are expected to arise from increased fibrosis. Our exploratory analyses provided internal validation of the clinical relevance of the primary outcome. However, all cosmesis, body image, and quality of life assessments were similar, indicating that fibrosis did not drive all of the patient experience. That there was no association of C−509T with cosmesis, despite its association with fibrosis, suggests that adverse cosmetic outcome is a multifactorial process attributable not simply to susceptibility to radiation fibrosis but also to disease, host, and surgical factors. Rather, we observed a significant association between preradiotherapy cosmesis and late fibrosis risk. Cosmetic outcome after surgery can reflect challenging anatomy, inferior surgical procedures, or poor wound healing, each of which could be expected to lead to a more fibrotic healing process. We speculate that this profibrotic environment enhances the development of late fibrosis after radiotherapy.
Clinically, the most apparent application of C−509T genotyping would be to aid in postradiation fibrosis risk assessment. Our data showed that patients homozygous for the −509C allele were at very low risk for fibrosis following standard breast radiotherapy doses. As one example, the decision of whether to include a tumor bed boost in patients with favorable tumor risk features may benefit from C−509T genotype information, although such a management application should be investigated prospectively before being applied broadly. Further investigations on the role of TGFB1 genotyping in lymphedema risk assessment and breast reconstruction decisions are ongoing.
Limitations
Late toxicities were evaluated 3 years after radiotherapy, but fibrosis as well as other radiotherapy-related toxicities can increase beyond this time point. Therefore, our study may underestimate the effect size of the C−509T allele. The present study was appropriately powered for the primary end point, yet the relatively small sample size limited post hoc subgroup analyses. This is notable regarding subgroup analysis by ethnicity because we observed enrichment of the risk allele among Hispanic patients but could not evaluate whether this subpopulation had a statistically elevated risk of fibrosis. The sample size also limited our ability to assess the effect of −509T homozygosity, which was present in only 14 patients but has previously been associated in retrospective studies with much higher fibrosis risk. 15 Because our study included only patients with early-stage cancer who received moderate radiation doses to the breast, it is difficult to evaluate the association between the TGFB1 genotype and the increased dose to the skin. Thus, it is unclear how the C−509T allele may affect fibrosis and functional outcomes among patients treated for locally advanced, inflammatory, or recurrent breast cancers.
Conclusions
In this prospective validation study, the C−509T allele was significantly associated with increased risk of grade 2 or higher breast fibrosis as assessed using LENT/SOMA criteria, breast atrophy, and adverse functional outcomes among patients with early-stage breast cancer 3 years after the completion of wholebreast radiotherapy. Genotyping patients to determine the presence of this polymorphism may assist with risk stratification, patient counseling, and potential therapeutic approaches for late radiotherapy toxicity. , not treated with chemotherapy, and treated with a radiation dose homogeneity within ±7% in the central axis plane. 22 For patients not meeting these criteria, the authors of the ASTRO guideline refused to render a recommendation as to the appropriateness of HF-WBI due to substantial disagreements regarding interpretation of the published literature and wide variation in practice patterns among the authors. The ASTRO guideline specifically highlighted two areas of ongoing controversy regarding HF-WBI: 1) whether or not it is safe to add a tumor bed boost following HF-WBI, and 2) whether or not it is safe to use HF-WBI in patients receiving anthracycline-or taxane-based chemotherapy. 22 The limited amount of data pertaining to use of HF-WBI in patients receiving a tumor bed boost and/or chemotherapy is a major obstacle to its widespread adoption in the United States, as approximately 85% of American radiation oncologists routinely use a tumor bed boost in their practice 23 and chemotherapy is routinely used for patients with tumors greater than 1 cm or node-positive disease. 24
With regard to a tumor bed boost, none of the patients in the Canadian randomized trial received a tumor bed boost. 17 Sixty-one percent of patients in the START A trial and 43% of those in the START B trial undergoing breast-conserving surgery received the optional tumor-bed boost of 10 Gy in 5 fractions. 20,21 Entry into the START trials was stratified by intention to give a tumor-bed boost, but the outcomes for whether a boost was actually used
have not yet been reported. 20,21 The RMH/GOC trial included a substudy in which 723 patients were randomized to receive no boost or a boost of 14 Gy in 7 fractions to the tumor bed. 18,19 The rates of IBTR in relation to the use of a boost have not been reported. Patients allocated to receive a boost had a higher risk of breast induration and telangiectasia than those who received no boost, but there was no difference between these groups in breast appearance (assessed photographically by a blinded observer), proportion of fair or poor cosmetic results, or risks of breast shrinkage, breast distortion, breast edema, arm swelling, or shoulder stiffness. However, results were not further divided according to whether patients received HF-WBI or CF-WBI, so it is not possible to determine whether one regimen was preferable when a boost was used. Further, the risk of a fair or poor cosmetic outcome in this trial was high (58-74% at 10 years), raising concern that the overall treatment plan did not result in optimal cosmesis, irrespective of assigned dose and use of a boost. One randomized trial including 1,024 women with invasive breast cancer 3 cm or smaller and negative surgical margins treated with HF-WBI (50 Gy in 20 fractions of 2.5 Gy) compared a tumor-bed boost of 10 Gy in 4 fractions or no boost. 25 With a median follow-up duration of 3.3 years, receipt of a tumor-bed boost was associated with a lower risk of IBTR, a higher risk of telangiectasia, and no difference in patient-reported cosmetic outcome. However, the relatively short length of follow-up in this trial precluded firm conclusions as to the long-term toxicity profile of a tumor-bed boost in patients receiving HF-WBI. In addition, the effective biologic dose of the HF-WBI regimen used in this trial was higher than that of the HF-WBI arms of the Canadian and START trials. 15,16,21
With regard to chemotherapy, anthracycline-containing and taxane-containing regimens were used in 25% and 1%, respectively, of patients in the START A trial and in 13% and 0.4%, respectively, of patients in the START B trial. 20,21 The fraction of patients receiving anthracyclines or taxanes in the Canadian and RMH/GOC trials was not reported, although it is likely that anthracyclines and taxanes were used very infrequently during the era in which those trials were conducted. 15, [17] [18] [19] Given the currently available data, the majority of experts comprising the ASTRO fractionation guideline task force reported that they routinely consider using HF-WBI in patients with early invasive breast cancer who have received chemotherapy or require a tumor bed boost, but a minority voiced concern that the currently published randomized data does not rule out an increased risk of normal tissue toxicity when HF-WBI is used sequentially with chemotherapy or a tumor bed boost. As a result, the ASTRO evidencebased guideline called for further investigation of HF-WBI for early invasive breast cancer in these two common clinical situations.
With regard to other clinical and pathologic selection criteria for use of HF-WBI, risk of IBTR after breast-conserving surgery followed by adjuvant WBI decreases as age increases, and is particularly high for younger women ages 40 and under. 26 The reasons for this discrepancy are not fully understood, but one possibility is that the sensitivity of breast cancer to radiation therapy may vary with age. Thus, it may be necessary to consider younger and older women as two distinct patient populations when evaluating the appropriateness of HF-WBI. Approximately 21% to 30% of patients enrolled in clinical trials comparing HF-WBI with CF-WBI were age 50 years or younger at diagnosis. 15-21 The effect of age on outcome has only been reported for the Canadian trial, which stratified entry by age (younger than 50 years versus 50 years or older). 15,17 A preplanned analysis found that HF-WBI was equivalent to CF-WBI in both groups. 15-17 However, the Canadian trial included only 305 women under 50, and no further division of results by age was performed within this group (e.g., age 40 years or younger versus age 41 to 49 years). Authors of the ASTRO whole breast fractionation guideline could not reach agreement on the appropriateness of HF-WBI for women under the age of 50 years; although the majority reported using HF-WBI for women under the age of 50 years, a minority felt that further data was needed. 22 Given this lingering uncertainty, for our trial we plan to exclude the youngest patients with the highest risk of recurrence (those under the age of 40 years) but include patients ages 40 years and older.
With regard to nodal status, radiation therapy to the supraclavicular fossa is generally indicated for patients with pathologic stage N2 or N3 breast cancer. Radiation therapy to the supraclavicular fossa is used on occasion for patients with N1 breast cancer who have additional risk factors for supraclavicular failure. To date, there is relatively little data regarding the safety of hypofractionated radiation to the supraclavicular fossa, and there is concern that such treatment could lead to a higher risk of late radiation-induced brachial plexopathy. However, for patients with N1 breast cancer for whom supraclavicular radiation is not planned, the ASTRO guideline indicates that "the majority of task force members thought that HF-WBI could be used", although few patients with these characteristics were included in the randomized trials. Accordingly, we plan to study patients with N0 or N1 breast cancer who will be receiving whole breast radiation alone without addition of a third field to treat the supraclavicular lymph nodes.
HF-WBI for DCIS
None of the prospective randomized trials comparing CF-WBI to HF-WBI included women with DCIS. 15,17-21 To the best of our knowledge, only one phase II study has examined the efficacy and safety of HF-WBI in the treatment of DCIS.27 This study enrolled 59 patients who have been followed for a median of 3 years and no ipsilateral breast tumor recurrences were reported. A total of 91% of patients experienced good or excellent cosmetic outcome based on physician report, but patient reported cosmetic outcomes were not included in this study.
Theoretically, it is expected that the documented equivalence of HF-WBI to CF-WBI for invasive breast cancer should also extend to DCIS. Nevertheless, given the fact that patients with DCIS have been excluded from the randomized trials comparing CF-WBI to HF-WBI, many radiation oncologists continue to be reluctant to recommend HF-WBI for patients with DCIS and the ASTRO fractionation guideline concluded that "that data were insufficient to allow an evidence-based recommendation for or against HF-WBI for women with DCIS". 22
Cosmetic outcome of WBI
In studying the side effect profile of WBI, a key outcome is the cosmetic result of the treated breast, which reflects not only the goal of breast conserving therapy (preservation of the breast with acceptable cosmesis) but also the extent to which normal tissue is damaged by radiation therapy. To date, however, none of the randomized trials to compare HF-WBI to CF-WBI have used a validated instrument to assess patient-reported cosmetic outcome. 15,17-21 The Canadian trial assessed cosmetic outcome using photographic assessment evaluated by a trained research nurse who was not blinded to the randomization arm. 15,17 In contrast, the START A and B trials did incorporate patientreported cosmetic outcomes, but rather than developing a validated instrument these trials simply asked patients about overall change in breast appearance using a four-point scale. 20,21 Another limitation of currently available randomized trials comparing HF-WBI to CF-WBI is that they were conducted in Canada and the United Kingdom, and it is not known whether cosmetic standards may differ between these countries and the United States. 28
To our knowledge, the best instrument available to assess patient-reported cosmetic outcome following BCS+WBI is the Breast Cancer Treatment Outcomes Scale (BCTOS), which was derived from a series of 185 women treated with BCS+WBI for DCIS or early invasive breast cancer. 29 This questionnaire consists of 22 items from which internally consistent subscales regarding cosmetic outcome, functional status, and breast pain were developed (Appendix G). Each item is rated on a scale of 1 to 4, with 1 indicating no difference between the treated and untreated breast and area, 2 indicating slight difference between treated and untreated breast and area, 3 indicating moderate difference between treated and untreated breast and area, and 4 indicating large difference between treated and untreated breast and area. Each subscale is calculated by computing the arithmetic mean of the answers for each of the items relevant to the given subscale. Thus, the score for each subscale is a continuous variable ranging from 1 to 4. In the original publication, the mean BCTOS cosmetic score was 2.24 with a standard deviation of 0.77 and a range of 1 to 4. Currently the BCTOS is being used in the pivotal phase III intergroup trial comparing WBI to accelerated partial breast irradiation (NSABP B-39/RTOG 0413).
Physician-reported cosmetic outcomes have been historically reported as a single four-level variable in RTOG trials: excellent, good, fair, and poor. 30 This scoring system derives from a scoring system developed at Harvard and is widely used in current literature (Appendix H). 31
Radiogenomic Predictors of Radiation Toxicity
In the past decade, interest has grown in identifying genomic polymorphisms that correlate with risk of radiation toxicity, under the premise that certain genetic polymorphisms correlate with an individual's baseline normal tissue radiosensitivity. 32-36 If such polymorphisms can be reliably identified and rigorously validated, their presence could be determined prospectively in patients, thereby impacting the decision to offer radiation therapy or selection of an appropriate radiation dose, allowing treatment to be tailored to an individual patient's genomic profile. To date, polymorphisms affecting DNA-repair pathways and the fibrotic response to tissue injury have been implicated as potentially associated with risk of radiation toxicity. 32-42 However, many of these studies investigated multiple polymorphisms with multiple putative outcomes, and thus risk of a false positive result was high due to the problem of multiple comparisons. Accordingly, confirmatory studies are essential to establish any one putative polymorphism as clinically relevant. One such polymorphism that has been identified in early studies is the C-509T variant allele in the transforming growth factor-beta (TGF-b) gene, with a study in 167 breast cancer patients reporting a statistically significant three-fold increased risk of radiation-induced fibrosis among patients who were heterozygous or homozygous for the variant allele, in comparison to wild type patients. This study used the Subjective, Objective, Medical Management, Analytic (SOMA) scale to assess late radiation-induced fibrosis. 43 Our collaborators in the Department of Epidemiology have already established their experience in measuring this allele and correlating its impact on risk of radiation pneumonitis in patients with lung cancer. 44
Rationale for Study Design
To gain further information regarding the safety and efficacy of HF-WBI in the treatment of DCIS and early invasive breast cancer, we plan to initiate a prospective randomized trial to compare HF-WBI to CF-WBI following conservative surgery for breast cancer. All patients will receive a tumor bed boost with a final dose dependant on final margin status. We will stratify patients according to chemotherapy (yes/no), margin status (< 2 mm vs > 2 mm), breast size (D cup or higher versus C cup or lower), and post-lumpectomy/pre-radiation physician-assessed cosmetic outcome. The primary objective of this study is to compare patient-reported cosmetic outcome at 3 years using the BCTOS for patients assigned to HF-WBI versus CF-WBI. Specifically, we will compare the 2 treatment arms with respect to the percent of women with adverse cosmetic scores at 3 years after completion of breast conserving surgery, as determined by the patient-reported BCTOS. A BCTOS cosmesis score of 2.5 or higher has been chosen a priori to indicate an adverse cosmetic outcome. Secondary aims will include comparing physician-assessed cosmetic outcome and risk of IBTR for patients treated with HF-WBI versus CF-WBI.
This study will address current concerns in the United States regarding adoption of HF-WBI by including a validated patient-reported cosmesis scale as the primary outcome measure and by including patients treated with a tumor bed boost with or without chemotherapy. In addition, investigating this question in women with DCIS will provide important data on the efficacy of HF-WBI in this sizeable patient cohort who were excluded from randomized trials of HF-WBI.
If HF-WBI is shown to confer cosmetic and tumor control outcomes comparable to CF-WBI, such a finding could help to promote its adoption in the United States, leading to major public health benefits, as HF-WBI is both more convenient and less expensive than CF-WBI. 14 In addition, improvements in the convenience of radiation therapy for DCIS could potentially increase utilization of radiation therapy following BCS for DCIS which is currently only approximately 50%. 45 In contrast, if this study demonstrates unacceptable cosmetic outcomes of HF-WBI in this cohort in the United States, such a finding would provide important evidence to suggest that HF-WBI should be studied carefully and cautiously prior to widespread adoption of HF-WBI for both DCIS and invasive breast cancer in the United States.
Thus, a study to evaluate patient-reported cosmetic outcomes for patients in the United States treated with HF-WBI followed by a tumor bed boost as compared to CF-WBI followed by a tumor bed boost should provide a meaningful addition to the literature that will help to guide radiation oncologists in the United States as they consider adopting HF-WBI.
As a secondary aim, we will conduct an optional, translational study to determine whether the C-509T variant allele of TGF-b is associated with an increased risk of late radiationinduced fibrosis. This study will help to confirm or refute the putative association of this allele with radiation toxicity, thereby bringing this finding either closer to clinical application or providing evidence that it should not be further explored.
Primary
2.1.1
To compare patient-reported cosmetic outcome at 3 years using the BCTOS for patients assigned to HF-WBI versus CF-WBI. Specifically, we will compare the 2 treatment arms with respect to the percent of women with adverse cosmetic scores at 3 years after completion of breast conserving surgery, as determined by the patient-reported BCTOS. A score of 2.5 or more indicates an adverse cosmetic outcome.
Secondary 2.2.1
To determine patient-reported cosmetic outcome using the BCTOS at 6 months, 1, 2, 4, and 5 years.
2.2.2
To determine physician-rated cosmetic outcome at 6 months, 1, 2, 3, 4, and 5 years using the Radiation Therapy and Oncology Group (RTOG) scale for physician assessment.30 Physician outcome will be determined using photographic assessment and scored by a panel of three attending physicians specializing in breast cancer who will be blinded to the patient randomization arm.
2.2.3
To determine the level of agreement between patient-rated cosmetic outcome and physician-rated cosmetic outcome at the various timepoints assessed.
2.2.4
To determine the 5-year and risk of pathologically-confirmed invasive and/or in situ ipsilateral breast tumor recurrence (IBTR) for patients with DCIS and early invasive breast cancer.
2.2.5
To determine patient-reported functional status and breast pain using the BCTOS at 6 months, 1, 2, 3, 4, and 5 years after treatment.
2.2.6
To determine maximal acute (within 6 weeks of treatment) and late (more than 6 weeks after treatment) skin and soft tissue toxicities using the NCI CTCAE v4.0 scale.
2.2.7
To determine the relationship between the volume of breast tissue receiving excessive dose (defined as greater than 105% of the prescription dose) and the risk of adverse cosmesis.
2.2.8
To determine the relationship between bra cup size and the risk of adverse cosmesis.
2.2.9
To determine whether there is a statistical interaction between breast volume and volume of tissue receiving greater than 105% of the prescription dose in predicting adverse cosmesis.
2.2.10
To determine in an exploratory analysis whether any other demographic, clinical, and pathologic factors correlate with risk of adverse cosmesis and risk of IBTR.
2.2.11
To determine if the C-509T variant allele of TGF-b is associated with an increased risk of grade 2 or higher fibrosis (as determined by the SOMA scale) three years after completion of radiation.
2.2.12
To compare the cost of radiation for the two treatment arms.
2.2.13
To compare patient quality of life, body image, and appearance investment for the two treatment arms using the FACT-B, Appearance Schemas Inventory-Revised (ASI-R), and Body Image Scale, respectively.
3.1
Conditions for patient eligibility 3.1.1 Pathologically confirmed ductal carcinoma in situ of the breast or early invasive breast cancer defined as pathologic stage Tis, T1, or T2, N0, N1mic, or N1a (pathologic staging of the axilla is required for all patients with invasive disease but is not required for patients with DCIS only).
3.1.2
Treatment with breast conserving surgery.
3.1.3
Final surgical margins must be negative, defined as no evidence for ductal carcinoma in situ or invasive breast cancer touching the inked surgical margin. If the invasive or in situ breast cancer approaches within less than 1 mm of the final surgical margin, then a reexcision is strongly encouraged. Lobular carcinoma in situ at the final surgical margin will be disregarded.
3.1.4
Age 40 years or older. This age cutoff is justified because breast cancers in women under the age of 40 are known to have a significantly higher risk of IBTR presumably due to underlying biologic differences. 10,22
3.1.5 Female sex.
3.1.6
Attending radiation oncologist declares intention to treat the whole breast only and that a third radiation field to treat regional lymph nodes is not planned (radiation of the undissected level I/II axilla with high tangents is allowed).
3.2.
Conditions for patient ineligibility 3.2.1 Pathologic or clinical evidence for a stage T3 or T4 breast cancer.
3.2.2
Pathologic evidence for involvement of 4 or more axillary lymph nodes, or imaging evidence of involvement of infraclavicular, supraclavicular, or internal mammary lymph nodes.
3.2.3
Clinical or pathologic evidence for distant metastases.
3.2.4
Any prior diagnosis of invasive or in situ breast cancer in either breast.
3.2.5
Current diagnosis of bilateral breast cancer.
3.2.6
If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer.
3.2.7
History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breast.
3.2.8
Patients must be enrolled on the trial within 12 weeks of the later of two dates: the final breast conserving surgical procedure or administration of the last cycle of concurrent cytotoxic chemotherapy.
3.2.9
Patients not fluent in English or Spanish. (The BCTOS will be available in these two languages)
3.2.10
Patient is pregnant.
4.1
The treating physician must document his/her intent to use whole breast irradiation without addition of a third field to treat regional lymph nodes (use of high tangent fields to treat the level I/II axilla is allowed; use of an electron field matched to the tangents fields to ensure adequate coverage of the in breast tumor bed is also allowed).
4.2
For patients with invasive cancer, the patient must have either completed chemotherapy, refused chemotherapy, or been evaluated by a medical oncologist who specified that chemotherapy was not recommended at this time.
5.1
Patients will be registered by the research nurse in the Breast Radiation Oncology Clinic at the University of Texas MD Anderson Cancer Center or by the staff within the Clinical Research Support Center for patients enrolled through the Regional Care Centers.
6.1
Treatment/Dose Specifications 6.1.1 External beam radiation therapy will be used exclusively in this study. Brachytherapy is not allowed.
6.1.2
Radiation therapy must begin within 12 weeks of the later of these two dates: the date of final breast conserving surgery or the date of the last infusion of cytotoxic chemotherapy.
6.1.3
The prescription dose for patients assigned to the HF-WBI arm will be 42.56 Gy in 16 fractions delivered to the whole breast on consecutive treatment days. A treatment day is defined as a normal business day, typically Monday -Friday excluding institutional holidays. The prescription dose for the tumor bed boost for patients assigned to HF-WBI will be 10 Gy in 4 fractions delivered on consecutive treatment days for patients with negative margins (> 2 mm from DCIS or invasive carcinoma and closest inked surgical margin) and 12.5 Gy in 5 fractions delivered on consecutive treatment days for patients with close surgical margins (< 2 mm from DCIS or invasive carcinoma and closest inked surgical margin). The boost will begin on the treatment day following completion of whole breast irradiation.
6.1.4
The prescription dose for patients assigned to the CF-WBI arm will be 50 Gy in 25 fractions delivered to the whole breast on consecutive treatment days. The prescription dose for the tumor bed boost for patients assigned to CF-WBI will be 10 Gy in 5 fractions delivered on consecutive treatment days for patients with negative margins (> 2 mm from DCIS or invasive carcinoma and closest inked surgical margin) and 14 Gy in 7 fractions delivered on consecutive treatment days for patients with close surgical margins (< 2 mm from DCIS or invasive carcinoma and closest inked surgical margin). The boost will begin on the treatment day following completion of whole breast irradiation.
6.1.5
In the event of severe acute toxicity during the course of radiotherapy (as determined by the treating physician), whole breast irradiation may be placed on hold for up to 3 treatment days and be replaced with the tumor bed boost to allow acute toxicity to subside. In this case, whole breast irradiation must resume upon discontinuation of the boost, and the total doses contributed from whole breast irradiation and the tumor bed boost will remain as stipulated in section 6.1.3 for patients in the HF-WBI arm and section 6.1.4 for patients in the CF-WBI arm.
6.1.6
The prescription points for whole breast irradiation and the tumor bed boost will be selected at the discretion of the treating radiation oncologist to balance target coverage versus dose homogeneity.
6.1.7
Inhomogeneity corrections will be used in dose calculations.
Technical Factors
6.2.1 Radiation will be delivered using a linear accelerator with a nominal energy > 6 MV.
6.2.2
Three-dimensional dose compensation will be used when needed to minimize dose inhomogeneity throughout the target volume using multileaf collimators and/or wedges.
6.2.3
Prone positioning may be utilized to improve normal tissue sparing when thought to be indicated by the treating radiation oncologist.
6.2.4
Respiratory gating with the deep inspiration breath hold technique may be utilized to minimize exposure of the heart to radiation when thought to be indicated by the treating radiation oncologist.
6.3
Localization, Simulation, and Immobilization
6.3.1
The tumor bed will be located on the basis of the treatment planning computed tomography scan supplemented by preoperative imaging data when available.
6.3.2
Patients will undergo computed tomography-based simulation with an axial slice thickness no greater than 5 mm.
6.3.3
Patients will be immobilized using a breast board and vacuum-lock bag or other institution-specific immobilization techniques in standard use at the discretion of their treating physician.
6.4
Treatment Planning/Target Volumes 6.4.1 Whole breast irradiation will be planned and delivered with traditional tangent fields, with the superior border set at approximately the inferior margin of the ipsilateral clavicular head, the medial border set at midline on the skin between the two breasts, the inferior border set 1-2 cm below in inframammary fold, and the lateral border set at approximately the mid-axillary line to ensure all palpable breast tissue is included within the fields. The posterior (deep) border of the medial and lateral tangent borders will be aligned to ensure that neither tangent field diverges into critical structures. A cardiac block may be utilized by the treating physician if it does not compromise coverage of the whole breast. Every effort should be made to minimize cardiac exposure.
6.4.2
Treatment of the level I/II axillary lymph nodes with high tangent fields is allowed. In such cases, the level I/II axillary lymph nodes should be contoured using the treatment planning CT images to assist with field delineation.
6.4.3
The clinical target volume will be defined as the seroma cavity and tumor bed clips (when present) as visualized on the treatment planning computed tomography scan. The clinical target volume will be trimmed such that it does not approach within 5 mm of the skin surface.
6.4.4
The tumor bed boost will be delivered with electrons or photons at the discretion of the treating radiation oncologist. The tumor bed boost will be delivered to the clinical target volume plus a radial margin of 1.5-2.0 cm at the discretion of the treating radiation oncologist. A second treatment planning computed tomography scan, with compression of the tumor bed or repositioning of the patient, may be obtained to assist in planning the tumor bed boost.
6.4.5
The treating physician should strive to minimize dose inhomogeneity within the breast. Any technique including the use of a wedge, three-dimensional dose compensation with a multi-left collimator, and/or intensity modulated radiation therapy is permitted. In treating the whole breast, use of an electron field matched to the tangent fields is allowed if needed to ensure adequate coverage of the tumor bed in the whole breast.
Critical Structures
6.5.1 With respect to the lung, no more than 3 cm of lung shall be included in the tangent field as measured from the rib-lung interface to the deepest aspect of the tangent field.
6.5.2
The heart shall be excluded or the cardiac volume minimized from the tangent fields. This can be achieved through use of a cardiac block, deep inspiration breath hold, or other geometric means.
6.6
Compliance Criteria 6.6.1 Plans will be considered acceptable if they adhere to the field borders as described in 6.4.1 and the clinical target volume is completely encompassed within the geometric projection of the tangent fields.
6.6.2
The treating physician shall treat the patient with CF-WBI, regardless of randomization arm, if either of the following occur: (1) in the judgment of the treating physician, the heart cannot be excluded from the fields without compromising tumor coverage; or (2) > 1 cubic centimeter of breast tissue is expected to receive > 108% of the prescription dose despite all efforts to optimize homogeneity.
6.6.3
A treatment break of up to 3 treatment days is acceptable. A break of 4 or more days will be considered a variation.
6.6.4
If the patient receives less than 95% of the intended whole breast radiation dose this will be considered a minor violation. If the patient receives less than 90% of the intended whole breast radiation dose this will be a major violation.
6.6.5
If, at the time of treatment planning, the treating physician feels that delivery of a tumor bed boost may be unsafe due to the clinical size of the seroma cavity, then the tumor bed boost may be omitted at the discretion of the treating radiation oncologist. This will be considered a variation, and patients not receiving a boost will be reported separately in outcomes analyses.
Radiation Therapy Quality Assurance Reviews
All cases will be presented for peer review in accordance with the policy of the Department of Radiation Oncology at The University of Texas M. D. Anderson Cancer Center.
Radiation Adverse Events
Events that may occur include fatigue, skin erythema, dry or moist desquamation, hyperpigmentation, alopecia, tenderness, and swelling. Uncommon side effects include breast cellulitis or abscess and severe breast pain. In the long term, breast changes may occur including fibrosis, hyper-or hypo-pigmentation, telangiectasia, shrinkage/breast asymmetry, poor cosmesis, and edema. Uncommon side effects that may occur after completion of radiation include upper extremity lymphedema, rib fracture, pneumonitis, pulmonary fibrosis, pericarditis, ischemic heart disease, and heart failure.
Adverse Events and Serious Adverse Events Reporting Requirements
We will follow institutional guidelines at the University of Texas M. D. Anderson Cancer Center.
Not applicable to this study.
All patients in this study will undergo breast conserving surgery, either with or without "oncoplastic" techniques including reduction mammoplasty. Placement of radio-opaque clips to define the extent of the lumpectomy cavity is encouraged but not required.
Permitted Supportive Therapy
All supportive therapy indicated for optimal medical therapy during the course of radiation will be permitted for this study. Supportive therapy will be documented as concomitant medication. Supportive therapy may include, but is not limited to, the following: Radiodermatitis creams or ointments Topical steroids Oral antipruritics Oral analgesics to include non-narcotic and narcotic medications Antibiotic therapy as indicated for breast infection Nutritional supplementation
Adjuvant Endocrine Therapy
Adjuvant endocrine therapy may be prescribed at the discretion of the treating medical oncologist but should begin after completion of radiation therapy.
10.1
Blood procurement. One-time 4-cc blood samples will be drawn into heparinized greentop tubes for each of the eligible subjects who grant consent. Blood drawn at the Main Campus will be hand delivered to Dr. Wei's laboratory, where the lymphocytes will be isolated for extraction of DNA for genotyping. Blood drawn at regional care centers will be sent via overnight mail to Dr. Wei's laboratory. Preprinted labels with study identification numbers will be placed on each blood tube. A transmittal slip (multiple-copy form) will accompany each blood sample, and a copy will be retained in the Study Coordinator's office.
10.2
The genotype of the C-509T, G915C, and T869C alleles of the TGF-b gene will be determined by Dr. Wei's laboratory using polymerase chain reaction restriction fragment length polymorphism assessment according to their previously published methods. 44
Study Parameters:
See Appendix I.
Evaluation During Study:
11.2.1 Patients will undergo weekly evaluations during radiation therapy, history and physical exam approximately 6 months after completing radiation therapy, and yearly history and physical exam for the 5 years following radiation therapy. Patients may be followed more frequently at the discretion of the treating radiation oncologist. After completing five years of follow up, patients will be off study and may be discharged to either the Institution's Cancer Survivors Clinic or to their primary medical doctor.
11.2.2
Patients will undergo surveillance mammography at the six month follow up visit, at the one year follow up visit, and yearly thereafter while on study
11.2.3
Abnormal findings on mammography or clinical exam will be further investigated with additional imaging modalities such as ultrasound. Findings that remain suspicious after additional imaging should be biopsied to determine the presence or absence of ipsilateral breast tumor recurrence.
Patient-Rated Evaluations
11.3.1
The Breast Cancer Treatment Outcomes Scale will be used to score cosmetic outcome from 1 to 4, with a score of 2.5 or higher indicating adverse cosmetic outcome (Appendix G).
11.3.2
The Breast Cancer Treatment Outcomes Scale will also be used to assess the domains of functional status and breast pain on a scale of 1 to 4, with a score of 2.5 or higher indicating adverse outcome (Appendix G).
11.3.3
The FACT-B is a validated instrument used to assess quality of life for women with breast cancer and will be used to assess general quality of life and will be scored according to standard guidelines that accompany the instrument.
11.3.4
The Body Image Scale (BIS) is a validated instrument that will be used to assess body image and will be scored according to standard guidelines for this instrument.
11.3.5
The Appearance Schemas Inventory-Revised (ASI-R) is a validated instrument to assess appearance investment and will be scored according to standard guidelines for this instrument.
11.3.6
The BCTOS, FACT-B, BIS, and ASI-R will be administered within 14 days prior to randomization and at the following timepoints measured from the date of completion of radiation therapy: 6 months, 1, 2, 3, 4, and 5 years.
Physician-Rated Evaluations:
Baseline physician-rated cosmesis will be scored by the treating radiation oncologist within 14 days prior to randomization using RTOG criteria. Patients will be stratified for randomization according to whether their treating physician rates their cosmetic outcome as excellent or good versus fair or poor (Appendix H). For documentation, photographs will be taken prior to radiation therapy as well. Photographs will be framed to include the low neck down to the upper abdomen and will be taken with arms at the side and patients will be asked to remove all jewelry prior to photography. Five views will be obtained: right lateral, right anterior oblique, anteroposterior, left anterior oblique, and left lateral. When possible, photographs will be obtained in the Department of Plastic Surgery three-dimensional photography suite, thereby enabling quantitation of breast size and position.
For follow up evaluations, photographs as described above will be obtained at 6 months, 1, 2, 3, 4, and 5 years from the date of completion of radiation therapy. A group of at least three attending physicians with expertise in breast cancer (physician specialty may include radiation oncology, surgical oncology, or plastic surgery), blinded to the randomization arm, will score the photographs using RTOG criteria. The average of the scores from the rating physicians will be the final physician-assessed cosmetic score for each timepoint after treatment. A mean physician-reported cosmetic score higher than 2.5 will be considered excellent/good cosmesis and a score less than or equal to 2.5 will be considered fair/poor cosmesis.
Treatment planning parameters
11.5.1
The volume of breast tissue receiving excessive dose > 105% of the prescription dose will be determined using treatment planning software.
11.5.2
Breast volume will be determined using the total volume of irradiated tissue receiving at least 90% of the prescription dose.
11.5.3
The maximal point dose within the breast will also be recorded.
11.5.4
The volume of the clinical target volume in cubic centimeters will be recorded.
11.5.5
The separation at the central axis will be recorded.
All data will be collected at The University of Texas M. D. Anderson Cancer Center and will be stored on HIPPAA-compliant institutional computer systems.
Primary Endpoint:
The primary endpoint for this study is the patient-reported cosmesis score on the BCTOS at 3 years after completing radiation therapy. Cosmesis scores range from 1 to 4, and scores of 2.5 or more indicate adverse cosmetic outcomes. Our objective is to show that the proportion of patients treated with HF-WBI with adverse cosmetic outcomes is not more than 10% greater than the proportion of patients treated with CF-WBI with adverse cosmetic outcomes.
A cutoff point of 2.5 was chosen in defining adverse cosmetic outcome for several reasons. First, if a patient scores 2.5 or higher, this means that, on average, they feel that their treated breast is at least moderately different from the untreated breast (ie they rated more domains as moderate or higher change rather than mild or less change). In the opinion of the clinical investigators on this trial, a patient-reported moderate difference between the treated and untreated breast is clinically relevant. Second, in the initial study using the Breast Cancer Treatment Outcomes Scale (BCTOS), the mean BCTOS cosmetic score was 2.23 with a standard deviation of 0.77. The BCTOS cosmetic score stratified at a cutoff of 2.5 was not reported. However, given the mean and standard deviation, we estimate that in the initial study of the BCTOS the percent of women with a cosmetic score of 2.5 or higher was approximately 35-40%. Our study's power calculation is based on the assumption that the adverse cosmetic score will be 35% in the HF-WBI arm and 40% in the CF-WBI arm. Accordingly, we believe that the cutoff we selected for defining adverse cosmesis will yield a risk of adverse cosmesis that is in concert with the assumptions built into our power calculation.
As reported in the START A and START B trials, 20,21 we expect the proportion of patients treated with CF-WBI experiencing an adverse cosmetic outcome at 3 years to be about 40%. For the current study, if we assume an alpha/beta ratio of 3.4 Gy for late normal tissue toxicity, 22 the equivalent doses in 2 Gy per fraction to the tumor bed in the HF-WBI arm are 58.7 Gy for patients with widely negative margins and 61.4 Gy for patients with close margins, slightly less than the tumor bed doses of 60 Gy and 64 Gy, respectively, that will be used in the CF-WBI. Accordingly, we make the a priori assumption that the risk of adverse cosmetic outcome will be slightly lower in the HF-WBI arm than in the CF-WBI arm.
Patients with early breast cancer are generally highly compliant with follow up care. For example, in the four main randomized trials comparing HF-WBI to CF-WBI (cited in the protocol), the number of patients lost to follow up ranged from 0% -1.3%. In addition, local failures requiring a mastectomy are rare in this population, typically less than 3% at 3 years. As a result, we do not anticipate patient drop out being a major concern. Nevertheless, as a conservative measure we plan to conduct a sensitivity analysis in which patients who do drop out prior to 3 years will be considered to have an adverse cosmetic outcome.
Sample Size:
If we assume that 35% of patients treated with HF-WBI will have adverse cosmetic scores and 40% of patients treated with CF-WBI will have adverse cosmetic scores, a sample size of 200 patients (100 randomized to each treatment arm) will yield 81% power with a 1-sided significance level of 0.10 for testing the following hypothesis:
where PHF-WBI is the proportion of patients treated with HF-WBI who have adverse cosmetic outcomes at 3 years and PCF-WBI is the proportion of patients treated with CF-WBI who have adverse cosmetic outcomes at 3 years.
Randomization:
Patients will be randomized to HF-WBI or CF-WBI using CORe. Randomization will be stratified by the post-lumpectomy/pre-radiation physician-reported cosmetic score (excellent/good versus fair/poor), bra cup size (D or higher versus C or lower), receipt of chemotherapy (yes/no), and margin status (< 2 mm vs > 2 mm).
Interim Analysis:
The accrual rate is expected to be 100 patients per year, and the primary outcome is measured at 3 years. Therefore, it is impractical to conduct an interim analysis of non-inferiority or futility.
Primary Analysis
13.5.1
We will use descriptive statistics to summarize the demographic and clinical characteristics of the patients by treatment arm.
13.5.2
We will use a chi-square test, stratified by randomization strata with a 1-sided significance level of 0.10 to test the hypothesis stated above. We will also estimate the proportion of patients in each treatment group with an adverse cosmetic outcome at 3 years with a 95% confidence interval.
Secondary Analyses
13.6.1 For each treatment arm we will tabulate the scores on the BCTOS at 6 months, 1, 2, 3, 4, and 5 years. Adverse cosmetic outcome will be defined as scores of 2.5 or more. We will use McNemar's test to assess changes in cosmetic outcome from 2 to 5 years and from 5 to 10 years within each treatment arm. We will use a chi-square test stratified by randomization strata to compare scores on the BCTOS for the two treatment arms at 2, 3, and 5 years.
13.6.2
For each treatment arm, we will tabulate the physician-rated cosmetic outcome using the Radiation Therapy and Oncology Group (RTOG) scale for physician assessment at 6 months, 1, 2, 3, 4, and 5 years. We will dichotomize the outcomes as excellent/good and fair/poor, and we will use McNemar's test to assess changes in cosmetic outcome from 2 to 5 years within each treatment arm. We will use a chi-square test stratified by randomization strata to compare scores for the two treatment arms at 6 months, 1, 2, 3, 4, and 5 years.
13.6.3
We will estimate with 95% confidence intervals the concordance between the BCTOS and the RTOG scale for physician assessment for classifying adverse cosmetic outcome at 6 months, 1, 2, 3, 4, and 5 years.
13.6.4
We will use the product-limit method of Kaplan and Meier to estimate with 95% confidence intervals the 5-year and 10-year probability of pathologically confirmed invasive and/or in situ ipsilateral breast tumor recurrence (IBTR) stratified by treatment arm and tumor type (DCIS or early invasive breast cancer). Patients will be censored at the time of death or distant recurrence.
13.6.5
For each treatment arm we will tabulate the patient-reported functional status and breast pain as measured by the BCTOS at 6 months, 1, 2, 3, 4, and 5 years. Scores of 2.5 or more will indicate adverse outcomes, and we will estimate with 95% confidence intervals the proportions of patients in each treatment arm with adverse outcomes at each assessment time.
13.6.7
For each treatment arm we will tabulate the maximal acute (within 6 weeks of completing treatment) and late (more than 6 weeks) skin and soft tissue toxicities using the NCI CTCAE v4.0 scale. In accordance with prior studies, we will also report the outcomes of fibrosis and telangiectasia using the SOMA scale. 43
13.6.8
We will use logistic regression methods to model the logit of the probability of patient reported adverse cosmetic outcome at each assessment time and the volume of breast tissue receiving >105% of the prescription dose as a function of treatment arm, breast size, and other demographic and clinical factors.
13.6.9
The one-sided Fisher's exact test will be used to test the association between the presence of at least one copy of the C-509T variant allele and risk of grade 2 or higher fibrosis at three years as reported using the SOMA scale. This strategy will yield 83% power to detect a 15% absolute difference in risk of grade 2 or higher fibrosis at a significance level of 0.05 assuming that 150 patients participate in this component of the study, the baseline risk of fibrosis in the wild type group is 5%, and the frequency of the variant allele in the population is 0.33. For hypothesis generation, we will use the twosided Fisher's exact test to test the association between the C-509T, G915C and T869C variant alleles in TGF-and early and late radiation-related toxicities captured using the CTCAE v4.0 and the risks of fibrosis and telangiectasia captured using the SOMA scale.
13.6.10
The cost of radiation for the two treatment arms will be compared using the Wilcoxon 2-sample test.
13.6.11
Data collected from the FACT-B, BIS, and ASI-R will be used to conduct exploratory analyses to identify putative cutpoints for these measures that could potentially discriminate between the two treatment arms. In addition, we will use longitudinal data analysis methods to describe how patient's scores for these measures may change over time and if treatment arm impacts this change.
Toxicity Monitoring
Within each treatment arm we will monitor the rate of CTCAE v4.0 grade 3 or higher acute radiation-induced dermatitis developed within 6 weeks of completion of radiation therapy. If we have reason to believe that the rate of acute dermatitis is more than 20% in either treatment arm we will stop the trial.
We will employ the following monitoring rule as a guide in assessing whether we are observing excess CTCAE v4.0 grade 3 or higher acute dermatitis. This rule is based on the method proposed by Thall et al. 46 We assume a beta(0.4, 1.6) prior distribution for the rate of CTCAE grade 3 or higher acute dermatitis. T his distribution has a mean of 20% and a standard deviation of 23%.
We will stop the trial if the Pr(CTCAE grade 3 or higher acute dermatitis > 20% | data) > 0.90 on either treatment arm. That is, if there is more than a 90% chance that the CTCAE grade 3 or higher acute dermatitis rate is more than 20% on either treatment arm we will stop the trial. We will monitor patients in cohorts of size 20 within each treatment arm. This monitoring rule gives us the following stopping boundaries. 
